Abstract
The effects of a single oral dose of 25 mg carvedilol on the plasma and urinary kinetics of digoxin after an oral and intravenous 0.5 mg dose, were investigated in two separate double-blind, placebo-controlled, period-balanced cross-over studies in healthy male subjects. Carvedilol increased the mean maximum plasma concentration and the area under the plasma concentration time-curve of digoxin when administered orally. The effects were virtually confined to the first 4 h after dosing, and the apparent terminal disposition rate constant was not changed. Carvedilol did not alter the plasma and urinary kinetics of intravenously administered digoxin.
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bertler A., Bergdahl B., Karlsson E. Letter: Plasma-digoxin concentrations after an intravenous loading dose. Lancet. 1974 Oct 19;2(7886):958–958. doi: 10.1016/s0140-6736(74)91168-4. [DOI] [PubMed] [Google Scholar]
- Cubeddu L. X., Fuenmayor N., Varin F., Villagra V. G., Colindres R. E., Powell J. R. Clinical pharmacology of carvedilol in normal volunteers. Clin Pharmacol Ther. 1987 Jan;41(1):31–44. doi: 10.1038/clpt.1987.6. [DOI] [PubMed] [Google Scholar]
- Meineke I. A simple BASIC program for the calculation of nonparametric confidence intervals in bioequivalence testing. Comput Methods Programs Biomed. 1987 Feb;24(1):65–71. doi: 10.1016/0169-2607(87)90067-8. [DOI] [PubMed] [Google Scholar]
- Rodin S. M., Johnson B. F. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet. 1988 Oct;15(4):227–244. doi: 10.2165/00003088-198815040-00003. [DOI] [PubMed] [Google Scholar]
- Sponer G., Bartsch W., Strein K., Müller-Beckmann B., Böhm E. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol. 1987 Mar;9(3):317–327. doi: 10.1097/00005344-198703000-00009. [DOI] [PubMed] [Google Scholar]
- Steinijans V. W., Diletti E. Generalization of distribution--free confidence intervals for bioavailability ratios. Eur J Clin Pharmacol. 1985;28(1):85–88. doi: 10.1007/BF00635713. [DOI] [PubMed] [Google Scholar]